1. Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations.
- Author
-
Guntermann C, Piaia A, Hamel ML, Theil D, Rubic-Schneider T, Del Rio-Espinola A, Dong L, Billich A, Kaupmann K, Dawson J, Hoegenauer K, Orain D, Hintermann S, Stringer R, Patel DD, Doelemeyer A, Deurinck M, and Schümann J
- Subjects
- Animals, Down-Regulation, Female, Gene Expression, Humans, Jurkat Cells, Male, Mice, Mice, Inbred C57BL, Rats, Rats, Inbred Lew, Rats, Sprague-Dawley, Receptors, Retinoic Acid genetics, Th17 Cells metabolism, Receptors, Retinoic Acid antagonists & inhibitors, Th17 Cells cytology, Thymus Gland pathology
- Abstract
Retinoic-acid-orphan-receptor-C (RORC) is a master regulator of Th17 cells, which are pathogenic in several autoimmune diseases. Genetic Rorc deficiency in mice, while preventing autoimmunity, causes early lethality due to metastatic thymic T cell lymphomas. We sought to determine whether pharmacological RORC inhibition could be an effective and safe therapy for autoimmune diseases by evaluating its effects on Th17 cell functions and intrathymic T cell development. RORC inhibitors effectively inhibited Th17 differentiation and IL-17A production, and delayed-type hypersensitivity reactions. In vitro, RORC inhibitors induced apoptosis, as well as Bcl2l1 and BCL2L1 mRNA downregulation, in mouse and nonhuman primate thymocytes, respectively. Chronic, 13-week RORC inhibitor treatment in rats caused progressive thymic alterations in all analyzed rats similar to those in Rorc -deficient mice prior to T cell lymphoma development. One rat developed thymic cortical hyperplasia with preneoplastic features, including increased mitosis and reduced IKAROS expression, albeit without skewed T cell clonality. In summary, pharmacological inhibition of RORC not only blocks Th17 cell development and related cytokine production, but also recapitulates thymic aberrations seen in Rorc -deficient mice. While RORC inhibition may offer an effective therapeutic principle for Th17-mediated diseases, T cell lymphoma with chronic therapy remains an apparent risk., Competing Interests: Conflict of interest: MLH works for CiToxLAB performing studies by order of Novartis. ADRE works for Novartis. All other authors work for and own shares or options of Novartis.
- Published
- 2017
- Full Text
- View/download PDF